HIND
VyomeยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HIND
Vyome Holdings, Inc.
A clinical-stage pharmaceutical company with multiple assets,focusing on immune and inflammatory diseases
Healthcare Equipment and Supplies
01/02/2008
10/06/2016
NASDAQ Stock Exchange
7
12-31
Common stock
18 Technology Dr. , Suite 110, Irvine, California 92618
--
Vyome Holdings, Inc., was incorporated on January 2, 2008 under the laws of the State of Delaware. ReShape Lifesciences Inc.and Vyome Therapeutics, Inc.have completed their merger on August 14, 2025. After the merger was completed, it was renamed Vyome Holdings, Inc. The company is primarily a clinical-stage pharmaceutical company with several assets focused on immune and inflammatory diseases.
Company Financials
EPS
HIND has released its 2025 Q1 earnings. EPS was reported at 19.52, versus the expected 0, beating expectations. The chart below visualizes how HIND has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HIND has released its 2025 Q3 earnings report, with revenue of 34.63K, reflecting a YoY change of -59.03%, and net profit of -8.60M, showing a YoY change of -1469.14%. The Sankey diagram below clearly presents HIND's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
